Recent published research on giant cell tumour of bone, curated from PubMed and updated monthly. Showing 117 publications from January 2025 onwards, organised by topic.
Last updated: 17 February 2026
BACKGROUND: For giant cell tumor of bone (GCTB) in the extremities, joint-preserving surgery (curettage) is often favored over en bloc resection to maintain postoperative function, although it carries a notable risk of local recurrence. We decided to develop a nomogram to predict the risk of loca...
INTRODUCTION: Giant cell tumor of bone (GCTB) is a rare but locally aggressive neoplasm which most commonly arises in the epiphyses of long bones of young adults. Occurrence in the mandible is uncommon, and hormone secreting variants are extremely rare. CASE PRESENTATION: We present the case of a...
BACKGROUND: Giant cell tumor of bone (GCTB) occurring in the femoral head and neck region presents significant therapeutic challenges due to its complex anatomy and aggressive biological behavior. This study aimed to analyse the clinical outcomes of preoperative denosumab therapy combined with cu...
BACKGROUND: Giant cell tumor of bone (GCTB) is a locally aggressive neoplasm with variable biological behavior. Programmed death-ligand 1 (PD-L1) has been implicated in tumor progression across multiple malignancies, but its relationship to growth kinetics in GCTB remains unclear. This study inve...
BACKGROUND: Although intraoperative magnetic resonance imaging (iMRI) is well established in neurosurgery, its role in musculoskeletal oncology remains unclear. PURPOSE: To assess the feasibility and safety of iMRI in bone and soft tissue tumor surgery, focusing on giant cell tumor of bone (GCTB)...
Giant cell tumor of bone (GCTB) rarely metastasizes, but pulmonary lesions pose therapeutic challenges. We report a woman in her 30s who developed multiple bilateral lung nodules 3.5 years after distal ulna GCTB resection and local recurrences. Denosumab 120 mg every 4 weeks was given for 2.5 yea...
When treating extremities affected by giant cell tumor of bone (GCTB), curettage should be performed to preserve the joint as much as possible in order to obtain a good functional outcome. The local recurrence risk is high following curettage, but new techniques are being developed to reduce loca...
INTRODUCTION: Giant cell tumor of the bone (GCTB) is a locally aggressive benign tumor involving the ends of the long bones seen in the second or third decade of life, more commonly in women. Even though it is benign, it has a potential for malignant transformation in 10% of cases and metastasis ...
BACKGROUND: Campanacci grade III and recurrent giant cell tumors (GCTs) of the distal radius are aggressive, but treatments are scare, and universally accepted surgical strategy has not been established. The purpose of this study was to compare the clinical outcomes of different surgical methods ...
OBJECTIVE: Giant cell tumor of the bone (GCTB) is a locally aggressive benign tumor with unpredictable recurrence patterns. While intraos seous recurrences are well-documented, soft tissue recurrence (STR) remains underrecognized. This study aimed to identify risk factors, radiographic features, ...
This retrospective cohort study evaluated the efficacy and safety of combining denosumab with curettage and bone grafting for distal radius giant cell tumor of bone. Patients treated between January 2020 and June 2023 were included if aged ≥18 years with histopathologically confirmed distal radiu...
AIMS: Giant cell tumor of bone (GCTB) is a rare, locally aggressive, intermediate-grade neoplasm. While typically benign, GCTB can exhibit atypical behavior, including indolent pulmonary metastases and malignant transformation. This study characterizes malignant and metastatic GCTB, distinguishin...
BACKGROUND: Giant cell tumor of bone (GCTB) is a benign but locally aggressive neoplasm with a high risk of recurrence. Among its patterns of relapse, soft-tissue recurrence (STR) is an uncommon but clinically significant entity, often presenting as ossified or non-ossified perilesional nodules. ...
BACKGROUND Periprosthetic joint infection (PJI) is a potentially catastrophic complication after orthopedic surgery. Biofilm formation and infection with multidrug-resistant pathogens significantly increase the difficulty of achieving successful treatment. CASE REPORT A 36-year-old woman presente...
BACKGROUND: Allograft-prosthesis composite reconstruction after periacetabular resections allows for bony union and internal repair, restoring bone stock for further revisions; the allograft-prosthesis composite can be shaped according to the pelvic resection to reconstruct the complex bone anato...
BACKGROUND: Although the significance of preoperative denosumab administration for giant cell tumor of bone (GCTB) is still controversial, sporadic reports have suggested a clinical benefit of administration prior to surgery for spinal GCTB. In this retrospective, multi-institutional study, we as...
BACKGROUND: Giant cell tumors of bone (GCTB) are RANK/RANK-ligand positive, progressive osteolytic tumors. There was no medical treatment for GCTB based on efficacy and safety data from Chinese patients. A single-arm, phase II study demonstrated the promising efficacy of JMT103 in unresectable or...
Given the lack of reliable indicators for predicting prognosis and treatment response in giant cell tumor of bone (GCTB) patients, this study aimed to identify new prognostic factors by analyzing the effect of tumor-associated macrophages (TAMs) on prognosis and denosumab treatment responsiveness...
OBJECTIVES: Giant cell tumor of bone (GCTB) is a locally aggressive tumor with a high recurrence rate. Using denosumab or its biosimilar in a neoadjuvant setting can facilitate limb-preserving surgery and reduce recurrence rates, with minimal side effects. MATERIAL AND METHODS: In this clinical a...
CASE: A 40-year-old man presented with malignant giant cell tumor of bone of the left distal femur. Despite distal femur resection/replacement and adjuvant chemotherapy, he experienced local recurrence and lung metastases. Salvage radiation therapy was ineffective. Biopsy of the tumor showed a PD...
Giant cell tumor of bone (GCTB) is an intermediate locally aggressive osteolytic tumor with low metastatic potential and a high recurrence rate. It comprises two main types of cells-neoplastic mononuclear stromal cells and osteoclast-like giant cells-which are responsible for the resorption of bo...
INTRODUCTION: Giant cell tumor (GCT) of bone is a benign but locally aggressive tumor, commonly affecting the epiphysis of long bones in young adults. Skip lesions in GCT - defined as discontinuous tumor foci within the same bone - are exceedingly rare, particularly in the appendicular skeleton. ...
Malignant giant cell tumor of bone (GCTB) is a rare malignant bone tumor. This analysis was conducted on patients with malignant GCTB at our center. The clinical, demographic, and prognostic characteristics were evaluated and compared. During 1 January 2015 to 31 December 2022, fifty patients wer...
Keratin positive giant cell rich tumor is a rare mesenchymal tumor first described in 2020. It can occur in both soft tissue and bone and predominantly affects young women. The tumor's biological behavior remains uncertain despite its low-grade classification. Characterized by keratin expression ...
RATIONALE: Giant cell tumors (GCTs) of the distal ulna are rare. Despite their benign nature, these tumors can exhibit local aggressiveness and have the potential to recur after undergoing conventional treatment involving curettage and bone grafting. For aggressive GCTs, radical resection is more...
Giant cell tumors (GCTs) of bone are uncommon neoplasms, typically located in the metaphysis of long bones, with rare occurrences in the spine, especially in the thoracic region. We report the case of a 34-year-old woman with a history of psoriasis and celiac disease, who presented with progressi...
BACKGROUND/OBJECTIVES: Denosumab has been considered effective for downstaging giant cell tumor of bone (GCTB), implying that it lowers the Campanacci grade rather than reducing tumor size. Preoperative tumor shrinkage holds therapeutic value by decreasing surgical complications. While previous s...
Giant cell tumors of bone (GCTB) are rare but aggressive, locally destructive tumors. They typically affect young people, significantly reducing their quality of life and increasing mortality rates. Giant cell tumors of bone are composed of osteoclast-like giant cells that respond to increased se...
Giant cell tumors of bone are locally aggressive, frequently harbor H3F3A p.G34W mutations, and rarely undergo malignant transformation. The pathogenesis of malignant transformation remains incompletely characterized. Herein, we present 28 malignant giant cell tumors of bone from 14 males and 14 ...
Giant cell tumors (GCTs) are benign but locally aggressive bone neoplasms that primarily affect skeletally mature individuals. They are characterized by a tendency for recurrence and being associated with significant morbidity. Traditional treatment has focused on surgical resection; however, the...
INTRODUCTION: Giant cell tumours (GCTs) are benign primary bone tumours that frequently present with local recurrence and occasionally malignant transformation to high-grade sarcoma. Surgery is the mainstay of treatment and generally consists of intralesional curettage. Denosumab was approved by ...
Posterior mediastinal masses frequently originate from neurogenic tumours; however, other possible causes include vascular abnormalities, cysts and primary bone tumours. We present a case involving a man in his 20s who experienced back pain, sudden sensorimotor weakness in both lower limbs and lo...
Background/Objectives: Despite the therapeutic potential of denosumab for the treatment of giant-cell tumors of the bone (GCTBs), there is a lack of standardization in treatment protocols. Methods: We present a multicenter, retrospective, descriptive study conducted across the seven hospitals in ...
BACKGROUND: Advancements in diagnostic and therapeutic modalities for giant cell tumors of bone (GCTB) have introduced molecular and radiological tools that refine clinical decision-making. H3.3 G34W immunohistochemical staining has become a routine diagnostic marker, while H3F3A mutational analy...
Denosumab, a RANK ligand inhibitor, is primarily used to prevent osteoclastogenesis in the treatment of conditions such as osteoporosis, bone metastasis, and giant cell tumor of bone (GCTB). RANK ligand also plays an important role in immunity by activating NF-κB and its target genes, including t...
Extraosseous giant cell tumor of bone (GCTB) associated with Paget disease of bone (PDB) is rare. We report a patient aged in their 70s with polyostotic PDB involving the skull, spine, and pelvis, previously treated with bisphosphonates, who presented with symptomatic hypercalcemia (calcium 14.8 ...
BACKGROUND AND OBJECTIVE: Giant cell tumor of bone (GCTB) is among the most prevalent benign primary bone tumors, characterized by its potential for aggressive local recurrence, soft tissue invasion, and, though rare, lung metastasis. Emerging evidence suggests unique behavioral patterns of GCTB ...
Giant cell tumor of the bone is a locally aggressive and rarely metastasizing tumor that typically affects the ends of long bones. Less than 1% of giant cell tumor of bone occur in the ribs. Our patients were a 32-year-old woman and a 45-year-old man and were detected following chest traumas. No ...
BACKGROUND: Giant cell tumor of bone (GCTB) is a rare, locally aggressive neoplasm that should be treated surgically, whenever possible. This treatment approach may be linked with greater morbidity besides functional impairment. Denosumab is a human monoclonal antibody. Its administration inhibit...
INTRODUCTION: Malignant giant cell tumor of bone (GCTB) is a very rare tumor, especially the primary type of it. We report a case of a young female who was diagnosed with a primary malignant giant cell tumor, in addition to a literature review of the previously reported cases. This case report ai...
Early surgical treatment of giant cell tumour of the bone has very good functional outcomes with a relatively low risk of local recurrence and metastatic spread.In case of a pathologic fracture, extraosseous extension, and tumor location in an anatomically difficult area, surgical treatment may r...
BACKGROUND: Preoperative denosumab has been an essential part of the management of giant cell tumor of bone (GCTB) which enhanced subchondral bone integrity and facilitated joint preservation surgery. However, evidence suggests that denosumab-induced sclerotic changes may potentially increase the...
Introduction: Giant cell tumor of bone (GCTB) is a rare, typically benign neoplasm that primarily affects long bones in adults, with clival involvement being extremely rare, particularly in pediatric cases: a mini-review shows a total of 28 described cases, of which only 5 were truly pediatric (w...
INTRODUCTION: Multicentric giant cell tumor of bone is extremely rare, accounting for less than 1% of all giant cell tumor of bone (GCTB) cases. Metachronous multicentric GCTB is even rarer. CASE PRESENTATION: We present a rare case of metachronous multicentric giant cell tumor of bone (GCTB) in ...
Denosumab is a human monoclonal antibody approved by the Food and Drug Administration in 2013 for use in adults with inoperable giant cell tumor of bone (GCTB). In children, it is used as an off-label drug in some giant cell-rich tumors of bone (GCRTB) and giant cell granuloma (GCG). The aim of t...
Giant-cell tumors of bone (GCTBs) are benign, expansile lesions usually found in the long bones of young adults. The authors report a pediatric skull base GCTB causing cranial nerve deficits and vision loss. The patient presented with blurry vision, left eye misalignment, headaches, nausea, and v...
INTRODUCTION: Giant cell tumors of bone (GCTBs) are locally aggressive tumors that can induce pathological fractures. Previous reports suggest that denosumab induces intratumoral ossification in β-catenin positive GCTB. However, its effect on the complete resection of GCTB with extraskeletal lesi...
OBJECTIVE: To analyze the evolution of patient/tumor characteristics and treatments for GCTB in the knee in Brazil over 30 years and assess changes in local recurrence rates. METHODS: Retrospective study of 335 patients (1989-2021) from 16 Brazilian centers. Data on patient/tumor characteristics,...
BACKGROUND: Denosumab represents a valuable treatment option for unresectable giant cell tumors of the bone (GCTBs). However, no standardized protocols exist determining the length of administration, with few studies having been published on patients who reached the end of treatment. AIMS: To ana...
Giant cell tumor of bone (GCTB) is a common locally aggressive junctional primary bone tumor, whose clinical treatment becomes more difficult once combined with pathological fracture. Extended curettage and en-bloc resection are common surgical procedures for treating GCTB, and drugs such as rece...
Giant cell tumour of bone (GCTB) is viewed as a benign, locally aggressive primary bone tumour with metastatic potential. Current management is surgery with bone curettage or resection and systemic therapy with denosumab. Diagnosis is confirmed histologically prior to surgery, with staging for pu...
BACKGROUND: Primary spine tumors are rare but can cause pain and neurological symptoms, occasionally requiring surgery. Previous national database studies have primarily focused on malignant spine tumors; however, data on primary intermediate spine tumors (PISTs) and primary benign spine tumors (...
BACKGROUND: Giant cell tumor of bone (GCTB) presents considerable complexity in tumor microenvironment (TME) because of its intricate intercellular heterogeneity and the presence of an immunosuppressive milieu. In order to understand the complex gene expression patterns and cell interactions in G...
INTRODUCTION: Bone gigantic cell tumours (BGCTs) are locally aggressive benign tumours, which can lead to significant functional impairment due to extensive bone destruction and soft tissue invasion and typically occur in the meta-epiphyseal region of long bones with the distal radius being the t...
BACKGROUND: Most distal radial giant cell tumors are treated with curettage, whereas malignancies and very advanced giant cell tumor of bone (GCTB) may be treated with resection. Wide resection can achieve good local control, but no consensus has been obtained on the optimal reconstruction method...
BACKGROUND: The reconstruction options for Enneking II/II+III pelvic tumors-defined as periacetabular tumor with or without involving the pubis or ischium-remain controversial. Short-term outcomes of ipsilateral femoral head autograft for the reconstruction of acetabular defects have been reporte...
A 25-year-old male patient presented to the emergency department with acute left knee pain and swelling after a fall. He had been experiencing left knee pain for several months. Examination revealed a swollen left knee held in a flexed position with limitation in range of motion. Plain radiograph...
In this article, a new modification technique is described to reconstruct large bone defects of the distal radius after en bloc giant cell tumor resection with a proximal vascularized fibula graft. We discuss anatomic landmarks during graft harvest as well as reconstructive considerations. We aim...
Giant cell tumours of bone are exceedingly rare in the distal phalanx of the thumb and pose therapeutic challenges when found in this location. We present a case of a giant cell tumour in this region, and a novel method of reconstruction to maintain length and function. LEVEL OF EVIDENCE: 5.
Giant cell tumors (GCTs) of bone are locally aggressive neoplasms that typically occur in the distal femur or proximal tibia. Infrequently, they may develop in the bones of the hand, including the distal phalanx. This case highlights the importance of a thorough and systematic diagnostic workup o...
The standard treatment for chronic osteomyelitis after trauma is affected bone resection and bone and soft tissue defect reconstruction. However, few reports exist regarding chronic osteomyelitis after bone tumor surgery. We retrospectively reviewed five cases of chronic infection after bone tumo...
BACKGROUND AND PURPOSE: Vascularized fibular grafting following tumor resection is an essential treatment option in limb salvage surgery. We aimed to evaluate: (I) bone healing, (II) complications and reoperations, (III) limb salvage, and (IV) survival. METHODS: We present a retrospective evaluat...
A 37-year-old man presented with swelling and erythema in the left first toe after a prior trauma, suspicious for osteomyelitis. X-ray and computed tomography (CT) scans revealed a radiolucent lesion with cortical disruption. A 99mTc/tricine/HYNIC ubiquicidin 29-41 (UBI) scintigraphy showed incre...
CASE: We present an unusual case of metachronous multicentric giant cell tumor (GCT) of forearm bones in a 38-year-old male patient with an 8-year follow-up. The diagnosis was established by imaging and histopathology. He underwent multiple surgeries with extraperiosteal resection of lesions with...
OBJECTIVE: To study the clinical presentation, surgical strategies, and outcomes in patients diagnosed with temporal bone giant cell tumors based on long-term follow-up. STUDY DESIGN: Retrospective cohort study. SETTING: Single-institutional. PATIENTS: This retrospective cohort study analyzed 7 p...
Giant cell tumor of the bone (GCTB) is a benign osseous neoplasm that primarily occurs in the epiphyses. Approximately 2% of GCTBs occur in the head and neck regions. Herein, we report a rare case of GCTB in the skull, which was discovered during a dental consultation. The patient was a 74-year-o...
INTRODUCTION: Giant cell tumor of bone (GCTB) is a benign but locally aggressive lesion, rarely affecting the carpus (<2% of hand GCTs), and is associated with recurrence rates up to 87%. Management of carpal GCT is challenging due to the limited bone volume, risk of damage to articular cartilage...
Giant cell tumor of bone (GCTB) is generally considered a benign tumor, but it can exhibit locally aggressive behavior. The two main surgical treatment options for GCTB are intralesional curettage and en-bloc resection. This study examined the long-term GCTB recurrence rates among Tunisian patien...
We evaluated the outcomes of ulnar translocation with T-locking plate fixation and ulnoscapholunate arthrodesis after distal radius resection for giant cell tumours. Eighteen patients (median age 33 years) were included, with a median follow-up of 72 months. The mean Musculoskeletal Tumour Societ...
Giant cell tumour (GCT) is a benign but locally aggressive bone tumour that affects the epiphyseal regions of long bones, with the distal radius involved in about 10% of cases. Treatment aims to completely remove the tumour, prevent recurrence and restore normal wrist and forearm function. Howeve...
BACKGROUND: Giant cell tumor of bone (GCTB) has a high potential for local recurrence after surgical treatment. It is characterized by the histological proliferation of osteoclast-like multinucleated giant cells. Tartrate-resistant acid phosphatase 5b (TRACP5b) is a reliable serum marker of bone ...
Giant cell tumor of bone (GCTB) is a benign neoplasm with aggressive behavior, predominantly affecting young adults. In the majority of these lesions, curettage is the treatment of choice; however, those classified as Campanacci grade III typically require extensive surgical resection, resulting ...
BACKGROUND: The management of distal radius giant cell tumors (GCTs) remains challenging, and the optimal approach is still a matter of debate. This systematic review and meta-analysis aimed to compare the outcomes of extended curettage and wide resection, the mainstays of treatment. METHODS: Med...
Primary talar bone tumors are rare. Surgical intervention on talar bone tumors is often challenging, even though most lesions are benign. Due to its unique anatomical and biomechanical characteristics, this surgical approach requires careful consideration. Although most benign talar tumors can be...
Introduction: Giant cell tumor of bone is accountable for 5–9% of primary bone tumors and is usually characterized by intermediate dignity and high recurrence rate. Numerous adjuvant procedures have been presented in the literature, however, their efficiency remains controversial, often due to lo...
Giant cell tumor (GCT) of the bone, although benign, demonstrates local aggressiveness, a potential for recurrence, and, in rare instances, malignant transformation. Functional preservation is crucial in cases involving the articular surface, often utilizing the Sandwich Technique. We propose an ...
PURPOSE: The goal of the study was to assess the result of en bloc resection and matched nonvascularized toe phalangeal transfer in Campanacci grade 2 or 3 giant cell tumors of the phalanges. METHODS: Seven patients with Campanacci grade 2 and 3 phalangeal giant cell tumors were treated by en blo...
BACKGROUND: Giant cell tumor of bone (GCTB) has been a common primary bone tumor with potential malignancy and local aggressiveness. H3F3A gene mutation has been gradually understood to be related with GCTB occurrence. However, the relationship between different mutation sites and tumor pathologi...
Giant cell tumor of bone (GCTB) is locally aggressive and rarely metastasizing mesenchymal tumor, molecularly characterized by the presence of H3-3A mutation. The management of GCTB is problematic because of local recurrence after curative surgical treatment, and complex biological and molecular ...
BACKGROUND: Giant cell tumours of the distal radius are highly aggressive local bone tumours. En bloc resection of Campanacci grade III giant cell tumours of the distal radius has been promoted as a reliable method for achieving local control, associated with the dual problem of bone defect recon...
INTRODUCTION: Conventional classification systems for giant cell tumors (GCTs) lack robust correlation with management and clinical outcomes. We propose a new radiologic classification system based on surgically relevant features to address this shortcoming. METHODS: This IRB-approved single-inst...
Hotspot mutations in H3-3A gene are key drivers in giant cell tumor of bone (GCTB). Rare primary bone sarcomas also harbor this mutation, but their clinicopathologic characteristics and molecular profiles, as well as their relationship to conventional and malignant GCTB (MGCTB) and high-grade con...
BACKGROUND: Pulmonary metastases of giant cell tumor of bone (GCTB) are rare and typically occur within several years of initial diagnosis or local recurrence. Here, we report a case with the longest documented interval-29 years-between the last local recurrence of GCTB and pulmonary metastasis, ...
The pulmonary parenchyma is the primary site of metastasis for giant cell tumor (GCT) of bone, a benign yet aggressive musculoskeletal tumor. Current treatments, including surgery and antibody therapy, are only partially effective and often lead to significant side effects. This study aimed to ev...
BACKGROUND: When managing aggressive giant cell tumor of bone (GCTB) around the knee joint, surgeons are often caught in a dilemma when determining whether to perform marginal excision or intralesional curettage. The purpose of this study was to report the long-term results of different treatment...
This case report presents a rare occurrence of a primary giant cell tumor (GCT) of bone with subsequent metastasis to the lung, undergoing osteosarcomatous transformation, with a significant temporal gap of 10 years between the two tumor events. A 32-year-old male initially presented with a prima...
Giant cell tumor of bone (GCTB) is a primary bone tumor that typically exhibits benign histological appearance and clinical behavior in most cases, with local aggressiveness and rare metastasis. It predominantly affects individuals in the young adult age group. It is characterized by the presence...
Bone primary malignant giant cell tumor (PMGCT) cases are extremely rare, and the optimal management remains unclear. This case report details the diagnosis and successful management of PMGCT in a 45-year-old female presenting with left knee pain, swelling, and restricted movement for one year. A...
Giant cell tumor of bone (GCTb), formerly also known as osteoclastoma, is a pathological entity that in veterinary medicine is still undefined and, probably, underdiagnosed. In humans, GCTb is recognized as a primary benign bone tumor, locally aggressive, with high local recurrence rates, with co...
Spinal giant cell tumors (GCTs) management primarily involves surgical resection; however, the optimal surgical approach continues to be a subject of debate. This study aims to comprehensively compare the efficacy of en-bloc resection with that of control resection techniques, specifically intral...
Giant cell tumor of bone (GCTB) is a benign but locally aggressive neoplasm that can rarely undergo malignant transformation, with a poor prognosis. The most frequent histotypes of the sarcomatous transformation of GCTB are osteosarcoma, fibrosarcoma, and undifferentiated pleomorphic sarcoma, and...
OBJECTIVE: Giant cell-rich lesions in the maxillofacial region are relatively rare, and comprehensive clinical differential diagnostic protocols are currently lacking. This article aims to provide a reference for the clinical diagnosis and treatment of giant cell-rich lesions. METHODS: This study...
INTRODUCTION: Giant cell tumor of bone (GCTB) ranks among the most prevalent locally aggressive tumor lesions, displaying a diverse range of biological behaviors. Recurrence of GCTB is well-documented, often attributed to microscopic tumour remnants remaining after intralesional curettage, with i...
BACKGROUND: Aneurysmal bone cysts (ABCs) are rare, benign bone lesions with distinct genetic and pathological characteristics. Secondary ABCs arising from giant cell tumors (GCTs) are associated with higher recurrence rates compared to primary ABCs. This study aimed to evaluate recurrence rates a...
BACKGROUND/AIM: Giant cell tumor of the bone (GCTB) is a locally-aggressive, benign tumor that typically affects young adults between 20 and 40 years old. CASE REPORT: A 15-year-old female presented to a primary care physician with pain in the lateral aspect of the left knee and was referred to o...
OBJECTIVES: To assess patient and tumor characteristics and treatment outcomes, focusing on local recurrence rates based on treatment type. METHODS: This is a retrospective review of cases of GCTB of the distal radius, identified from the databases of 74 patients in Brazilian institutions special...
Epiphyseal and metaphyseal bone lesions in pediatric patients are uncommon, and lesions that cross an open physis are even rarer. The differential diagnosis for such lesions consists of infection, giant cell tumor, and chondroblastoma. We describe a 4-year-old male patient who presented with a bo...
PURPOSE: This study aims to explore the feasibility of MRI-based habitat and peritumoral radiomics for predicting the proliferative activity of stromal cells in giant cell tumor of bone (GCTB). MATERIAL AND METHODS: A retrospective study was performed on 133 patients (102 in training cohort and 3...
OBJECTIVE: To evaluate the immunoexpression of programmed cell death protein 1 (PD-1) and programmed cell death ligands 1 (PD-L1) and 2 (PD-L2) in giant cell granulomas of the jaws (central giant cell granuloma [CGCG], peripheral giant cell granuloma [PGCG]) and giant cell tumor of bone (GCTB). D...
Giant cell tumor of bone (GCTB) is a rare, benign but locally aggressive neoplasm that typically arises in the epiphysis of long bones. GCTB occurrence in the axial skeleton is less common. Due to its variable radiological appearance and unusual location, GCTB can be misdiagnosed as a soft tissue...
Though the diagnostic utility of H3.3G34W immunohistochemistry (IHC) for giant cell tumor of bone (GCTB) is well established, it is limited by a proportion of cases with variant H3-3A mutations [H3-3A: c.104G>T p. Gly35Val (G34V), H3-3A: c.103G>A p. Gly35Arg (G34R), H3-3A: c.103_104delinsCT p. Gl...
Bone and soft tissue sarcomas are a highly heterogeneous group of rare cancers of mesenchymal origin. Treatment options other than surgery have limited efficacy due to low response rates with some exceptions. Radioligand therapy targeting prostate-specific membrane antigen (PSMA) may provide a no...
Though anti-histone H3.3G34W antibody is highly sensitive to giant cell tumours of bone, a subset of tumours which are negative on immunohistochemistry harbours variant H3F3A mutations. In this study, the diagnostic utility of anti-histone H3.3G34V and R immunohistochemistry was assessed along wi...
BACKGROUND: Giant cell tumor of bone is a locally aggressive bone tumor characterized by the proliferation of round-to-oval mononuclear cells and uniformly distributed osteoclast-type giant cells. Giant cell tumor of bone typically arises in long bones, whereas craniofacial involvement is rare. A...
OBJECTIVE: To investigate the clinical and imaging characteristics of giant cell tumors (GCT) in patients aged 18 and under. METHODS: This retrospective study analyzed clinical and imaging data from 12 patients aged 18 and below with histopathologically confirmed GCT, treated at xxx hospital from...
OBJECTIVE: Five cases of giant cell tumor of bone (GCTB) in the head and neck region were reported, with a main focus on the radiological findings to identify common characteristics for the diagnosis of GCTB in these sites. MATERIALS AND METHODS: Five consecutive patients diagnosed with GCTB were...
Giant cell tumour of the bone (GCTB) occurring in paediatric patients is rare and may presents with atypical histology. Given that giant cell tumour mimics, such as osteosarcoma, are more prevalent in this demographic, diagnosing GCTB can often be challenging. This study aimed to investigate the ...
Brown tumor is usually caused by primary or secondary hyperparathyroidism but is exceptionally rare after kidney transplantation. Their rarity and atypical pathological features make diagnosis and treatment particularly challenging. We present a case of a 38-year-old woman with multiple brown tum...
Tumor-derived osteochondral defects (OCDs) pose significant clinical challenges, necessitating integrated strategies for local tumor ablation while preserving the regenerative niche and enabling coordinated cartilage and subchondral bone repair. Herein, we introduce a spatiotemporal microneedle (...
Many benign and malignant bone and soft tissue tumors can contain giant cells in variable amounts. In some tumors, such as tenosynovial giant cell tumor and giant cell tumor of bone, these osteoclast-like giant cells are so prominent and characteristic that their presence has defined the entity. ...
Objective: Giant cell lesions (GCLs) share similar histopathologic features. The influence of immune involvement on the biology of giant cell lesions remains largely elusive. This study aimed to evaluate and compare lymphocyte and mast cell infiltration and distribution among three giant cell les...
Quercetin, a flavonoid derived from plant sources, has been extensively studied for its numerous biological properties, particularly its potential antitumor action against various malignant neoplasms. In our experience with a giant cell tumor of bone cell line (TIB-223), we demonstrated that quer...
OBJECTIVE: To investigate the metabolic remodeling and functional specialization of immune cells within the tumor microenvironment (TME) of bone tumors, including Ewing's sarcoma, osteosarcoma, and giant cell tumor of bone, through high-resolution single-cell RNA sequencing (scRNA-seq) analysis. ...
BACKGROUND: Giant cell tumor of bone (GCTB) represents a group of tumors that characterized by their heterogeneity and the presence of multiple cell types. It is essential to understand their molecular mechanisms for better designing therapeutic approaches. METHODS: We applied single cell RNA-seq...